Solanaceous alkaloids – Ipratropium bromide MCQs With Answer

Solanaceous alkaloids – Ipratropium bromide MCQs With Answer

Solanaceous alkaloids such as atropine and scopolamine inspired development of clinically important anticholinergic drugs; among them, ipratropium bromide is a quaternary ammonium derivative widely used as an inhaled bronchodilator. This concise guide for B. Pharm students covers pharmacology, mechanism of action, formulation, pharmacokinetics, adverse effects, drug interactions and therapeutic uses of ipratropium, linking its solanaceous origin to clinical practice. Emphasis is placed on receptor selectivity (muscarinic antagonism), inhalation delivery systems (MDI, nebulizer), and patient counselling points. Clear, exam-oriented MCQs with explanations will reinforce learning and prepare you for pharmacology and therapeutics assessments. Now let’s test your knowledge with 50 MCQs on this topic.

Q1. Which of the following best describes ipratropium bromide’s chemical class?

• Quaternary ammonium antimuscarinic
• Tertiary amine beta-agonist
• Catecholamine bronchodilator
• Corticosteroid

Correct Answer: Quaternary ammonium antimuscarinic

Q2. Ipratropium bromide is derived structurally from which family of natural alkaloids?

• Solanaceous alkaloids
• Opioid alkaloids
• Isoquinoline alkaloids
• Pyrrolizidine alkaloids

Correct Answer: Solanaceous alkaloids

Q3. The primary mechanism of action of ipratropium bromide in the airways is:

• Muscarinic receptor antagonism leading to bronchodilation
• Beta-2 receptor agonism causing smooth muscle relaxation
• Inhibition of phosphodiesterase enzymes
• Stimulation of alpha-adrenergic receptors

Correct Answer: Muscarinic receptor antagonism leading to bronchodilation

Q4. Which muscarinic receptor subtype is most important for bronchial smooth muscle contraction that ipratropium blocks?

• M3
• M1
• M2
• M4

Correct Answer: M3

Q5. Compared to atropine, ipratropium bromide has which pharmacokinetic advantage?

• Poor CNS penetration due to quaternary ammonium structure
• Higher oral bioavailability
• Longer systemic half-life enabling once-daily dosing
• Greater ability to cross the blood–brain barrier

Correct Answer: Poor CNS penetration due to quaternary ammonium structure

Q6. The main clinical indications for inhaled ipratropium include:

• Chronic obstructive pulmonary disease (COPD) and adjunct therapy in asthma
• Primary treatment for pulmonary embolism
• First-line monotherapy for acute severe asthma in adults
• Management of bacterial pneumonia

Correct Answer: Chronic obstructive pulmonary disease (COPD) and adjunct therapy in asthma

Q7. Which formulation(s) is/are commonly available for ipratropium bromide?

• Metered-dose inhaler (MDI) and nebulizer solution
• Oral tablets and subcutaneous injection
• Transdermal patch and suppository
• Intravenous infusion only

Correct Answer: Metered-dose inhaler (MDI) and nebulizer solution

Q8. A pharmacological property of ipratropium due to its quaternary structure is:

• Limited systemic absorption after inhalation
• High oral absorption and first-pass metabolism
• Strong central sedation
• High lipid solubility leading to accumulation in brain tissue

Correct Answer: Limited systemic absorption after inhalation

Q9. The most common local adverse effect of inhaled ipratropium is:

• Dry mouth
• Tachycardia leading to myocardial infarction
• Severe systemic anticholinergic toxicity
• Renal failure

Correct Answer: Dry mouth

Q10. Which of the following systemic anticholinergic effects is least likely with inhaled ipratropium?

• Central nervous system confusion
• Bitter taste and dry throat
• Mild urinary retention in susceptible patients
• Increased intraocular pressure if it contacts the eye

Correct Answer: Central nervous system confusion

Q11. Ipratropium bromide is often co-administered with which drug class for additive bronchodilation?

• Short-acting beta-2 agonists (SABA)
• Loop diuretics
• ACE inhibitors
• Systemic corticosteroids only

Correct Answer: Short-acting beta-2 agonists (SABA)

Q12. Which statement about ipratropium’s onset and duration of action is correct?

• Onset ~15 minutes; duration ~4–6 hours
• Onset within seconds; duration >24 hours
• Onset after 6 hours; duration 48 hours
• Immediate onset; duration 15 minutes

Correct Answer: Onset ~15 minutes; duration ~4–6 hours

Q13. The brand name commonly associated with ipratropium bromide is:

• Atrovent
• Ventolin
• Flovent
• Spiriva

Correct Answer: Atrovent

Q14. Which property explains why ipratropium has minimal central adverse effects compared to tertiary amines?

• Permanent positive charge on the quaternary nitrogen limits BBB crossing
• Rapid hepatic activation into inactive metabolites
• High protein binding prevents central distribution
• It is rapidly pumped out by P-glycoprotein in the brain

Correct Answer: Permanent positive charge on the quaternary nitrogen limits BBB crossing

Q15. Which of the following patients requires caution when using ipratropium?

• Patient with narrow-angle glaucoma after poor inhaler technique
• Patient with controlled hypertension only
• Patient with type 2 diabetes well-controlled with diet
• Patient using topical antifungal cream

Correct Answer: Patient with narrow-angle glaucoma after poor inhaler technique

Q16. What is the expected effect of ipratropium on airway secretions?

• Reduction of cholinergically mediated bronchial secretions
• Marked increase in bronchial secretions
• No effect on secretions, only on smooth muscle
• Production of purulent sputum

Correct Answer: Reduction of cholinergically mediated bronchial secretions

Q17. Which of the following is a correct counseling point for patients using ipratropium MDI?

• Avoid getting the spray into the eyes to prevent blurred vision or eye pain
• Swallow the aerosol for better effect
• Use it only once a week regardless of symptoms
• Rinse mouth with alcohol after each use

Correct Answer: Avoid getting the spray into the eyes to prevent blurred vision or eye pain

Q18. In COPD management guidelines, inhaled ipratropium is classified as which type of bronchodilator?

• Short-acting muscarinic antagonist (SAMA)
• Long-acting beta-2 agonist (LABA)
• Inhaled corticosteroid (ICS)
• Leukotriene receptor antagonist

Correct Answer: Short-acting muscarinic antagonist (SAMA)

Q19. Which metabolic or elimination route is most relevant for ipratropium?

• Primary renal excretion of unchanged drug
• Extensive metabolism to active metabolites in the liver
• Exhalation unchanged as the main elimination route
• Fecal elimination after biliary excretion only

Correct Answer: Primary renal excretion of unchanged drug

Q20. A pharmacology exam question: why is ipratropium less likely to cause tachycardia than systemic antimuscarinics?

• Because inhaled delivery limits systemic absorption and cardiac muscarinic blockade
• Because it is a selective M1 antagonist that spares cardiac M2 receptors
• Because it is a beta-blocker in addition to antimuscarinic actions
• Because it causes reflex bradycardia via central mechanisms

Correct Answer: Because inhaled delivery limits systemic absorption and cardiac muscarinic blockade

Q21. Ipratropium is least effective as a bronchodilator in which scenario?

• Acute severe bronchospasm as monotherapy
• Stable COPD to relieve bronchoconstriction
• Adjunctive therapy with SABA in acute exacerbation
• Reducing cholinergic bronchomotor tone in chronic disease

Correct Answer: Acute severe bronchospasm as monotherapy

Q22. Which structural feature distinguishes ipratropium from tertiary amine antimuscarinics?

• Permanent positive charge on nitrogen (quaternary ammonium)
• Presence of an ether linkage at the aromatic ring
• Prodrug ester that converts in vivo to atropine
• Large lipophilic substituent allowing BBB entry

Correct Answer: Permanent positive charge on nitrogen (quaternary ammonium)

Q23. Which side effect requires immediate attention and discontinuation of ipratropium if suspected?

• Acute angle-closure glaucoma symptoms after eye exposure
• Mild dry mouth resolving in hours
• Temporary bitter taste after inhalation
• Non-productive cough for a day

Correct Answer: Acute angle-closure glaucoma symptoms after eye exposure

Q24. Which statement about ipratropium’s interaction profile is correct?

• Concurrent use with other anticholinergics can increase anticholinergic effects
• It has clinically significant interactions with ACE inhibitors causing hyperkalemia
• It strongly inhibits CYP3A4, causing multiple drug interactions
• It neutralizes the effect of beta-agonists when co-administered

Correct Answer: Concurrent use with other anticholinergics can increase anticholinergic effects

Q25. For nebulizer administration in adults, a commonly used ipratropium dose is:

• 500 micrograms (0.5 mg) per nebulization
• 10 mg per nebulization
• 50 micrograms once daily
• 2 grams per nebulization

Correct Answer: 500 micrograms (0.5 mg) per nebulization

Q26. Which laboratory monitoring is routinely required for patients on inhaled ipratropium?

• No routine laboratory monitoring is typically required
• Weekly serum creatinine monitoring due to nephrotoxicity
• Frequent serum potassium levels due to hypokalemia risk
• Monthly liver function tests due to hepatotoxicity

Correct Answer: No routine laboratory monitoring is typically required

Q27. Which of these is a correct statement about ipratropium and pregnancy?

• Use only if clearly needed; limited human data but topical inhaled use is common
• It is absolutely contraindicated in all trimesters
• It is a documented teratogen and must be avoided
• It is recommended as the first-line obstetric bronchodilator

Correct Answer: Use only if clearly needed; limited human data but topical inhaled use is common

Q28. Stability and storage advice for ipratropium inhaler includes:

• Store at room temperature away from direct heat and light
• Store frozen to maintain potency
• Keep in direct sunlight to avoid precipitation
• Open bottle must be refrigerated immediately

Correct Answer: Store at room temperature away from direct heat and light

Q29. Which patient counselling point is important for combined ipratropium and salbutamol nebulizer therapy?

• Use bronchodilator (salbutamol) first, then ipratropium for best bronchodilation
• Mix with antibiotics in the same nebulizer without checking compatibility
• Stop using bronchodilators when symptoms improve and never seek further care
• Always swallow nebulizer solution after inhalation

Correct Answer: Use bronchodilator (salbutamol) first, then ipratropium for best bronchodilation

Q30. Which adverse effect is more likely if ipratropium solution accidentally enters the eye?

• Increased intraocular pressure and blurred vision
• Marked reduction in visual acuity due to retinal detachment
• Instantaneous miosis and pupillary constriction
• Immediate cataract formation

Correct Answer: Increased intraocular pressure and blurred vision

Q31. In terms of receptor selectivity, ipratropium is best described as:

• Non-selective muscarinic antagonist with clinical effect mainly at M3 receptors
• M2 selective agonist
• Beta-1 selective antagonist
• Alpha-2 adrenergic agonist

Correct Answer: Non-selective muscarinic antagonist with clinical effect mainly at M3 receptors

Q32. The rationale for combining ipratropium with a long-acting bronchodilator in COPD maintenance is:

• Complementary mechanisms provide greater bronchodilation and symptom control
• To reduce mucociliary clearance permanently
• To increase corticosteroid systemic absorption
• To cause tolerance and diminish efficacy over time

Correct Answer: Complementary mechanisms provide greater bronchodilation and symptom control

Q33. Which of the following is true regarding ipratropium’s systemic bioavailability after inhalation?

• Low systemic bioavailability due to limited absorption and local action
• Very high systemic bioavailability approaching 90%
• Completely metabolized in the lungs into inactive peptides
• Acts as a prodrug activated in systemic circulation

Correct Answer: Low systemic bioavailability due to limited absorption and local action

Q34. Which adverse effect is a potential concern in elderly patients using ipratropium?

• Urinary retention due to anticholinergic effects
• Severe hypoglycemia due to increased insulin release
• Progressive hearing loss within days
• Immediate severe neutropenia

Correct Answer: Urinary retention due to anticholinergic effects

Q35. For B. Pharm students studying medicinal chemistry, ipratropium’s quaternary ammonium contributes to which property?

• Permanent positive charge leading to poor lipid solubility
• Neutral pH-dependent ionization similar to tertiary amines
• Ability to form covalent bonds with muscarinic receptors
• Conversion to lipid-soluble metabolites easily crossing membranes

Correct Answer: Permanent positive charge leading to poor lipid solubility

Q36. Which adverse reaction suggests a hypersensitivity to ipratropium?

• Bronchospasm, rash, or angioedema after inhalation
• Transient mild dry mouth only
• Temporary bitter taste lasting minutes
• Expected reduction in sputum production

Correct Answer: Bronchospasm, rash, or angioedema after inhalation

Q37. Ipratropium’s role in acute asthma exacerbation is best summarized as:

• An adjunct to beta-agonists, particularly in severe exacerbations
• The preferred single agent for all acute exacerbations
• Contraindicated in all cases of acute asthma
• Primarily an anti-inflammatory agent

Correct Answer: An adjunct to beta-agonists, particularly in severe exacerbations

Q38. Which of the following accurately describes ipratropium’s effect on mucociliary clearance?

• It may reduce excessive cholinergic secretion but generally preserves mucociliary function
• It permanently abolishes mucociliary clearance
• It increases mucus viscosity dramatically leading to airway obstruction
• It converts ciliated epithelium to secretory goblet cells

Correct Answer: It may reduce excessive cholinergic secretion but generally preserves mucociliary function

Q39. Which formulation consideration is important for pharmacists preparing ipratropium nebulizer admixtures?

• Compatibility with other nebulized drugs should be checked before mixing
• Any concentration can be used without consideration of osmolarity
• It must always be mixed with sodium bicarbonate to activate it
• It requires refrigeration immediately after mixing

Correct Answer: Compatibility with other nebulized drugs should be checked before mixing

Q40. Which clinical sign would most likely indicate excessive anticholinergic effect from ipratropium?

• Marked dry mouth, urinary retention, and constipation in a susceptible patient
• Profuse sweating and lacrimation
• Hypersalivation and diarrhea
• Bradycardia with increased sweating

Correct Answer: Marked dry mouth, urinary retention, and constipation in a susceptible patient

Q41. In comparing ipratropium with tiotropium, a long-acting muscarinic antagonist (LAMA), which is true?

• Ipratropium is short-acting and requires more frequent dosing than tiotropium
• Ipratropium provides once-weekly dosing while tiotropium is TID
• Both are primarily beta-agonists with identical duration
• Ipratropium is more selective for M3 and has 24-hour action

Correct Answer: Ipratropium is short-acting and requires more frequent dosing than tiotropium

Q42. Which quality control parameter is most relevant for ipratropium inhaler manufacturing?

• Metered dose and spray particle size distribution for effective lung deposition
• Colorimetric assay for chlorhexidine contamination
• Fermentation purity levels similar to antibiotics
• Radioactivity screening due to isotopic labeling

Correct Answer: Metered dose and spray particle size distribution for effective lung deposition

Q43. Which statement about ipratropium’s receptor kinetics is accurate?

• It reversibly blocks muscarinic receptors without intrinsic activity
• It is an irreversible muscarinic agonist
• It acts as a partial M3 agonist increasing tone
• It permanently downregulates muscarinic receptors

Correct Answer: It reversibly blocks muscarinic receptors without intrinsic activity

Q44. For pediatric use, which point is relevant for ipratropium dosing and administration?

• Dosing is weight-based for nebulizer solutions; MDIs require spacer use in young children
• Children should only receive oral ipratropium tablets
• Ipratropium is contraindicated in all children under 18 years
• Pediatric dosing is identical to adult dosing irrespective of weight

Correct Answer: Dosing is weight-based for nebulizer solutions; MDIs require spacer use in young children

Q45. Which pharmacodynamic effect explains ipratropium’s benefit in COPD patients with chronic bronchitis?

• Reduction in cholinergic bronchoconstriction and bronchial secretions
• Direct antibacterial action against respiratory pathogens
• Systemic anti-inflammatory steroid-like effects
• Enhancement of mucous hypersecretion to trap particles

Correct Answer: Reduction in cholinergic bronchoconstriction and bronchial secretions

Q46. During formulation development, why is the bromide salt form used for ipratropium?

• Salt formation increases stability and water solubility for inhalation solutions
• Bromide makes the drug volatile for inhalation as a gas
• Bromide converts the drug into a prodrug requiring activation
• The bromide causes irreversible binding to muscarinic receptors

Correct Answer: Salt formation increases stability and water solubility for inhalation solutions

Q47. Which adverse effect might indicate inadvertent systemic exposure to ipratropium (for example, swallowing spray)?

• Increased heart rate and mild systemic anticholinergic effects
• Profound hypoglycemia and tremors
• Severe hyperkalemia within minutes
• Immediate arterial thrombosis

Correct Answer: Increased heart rate and mild systemic anticholinergic effects

Q48. Which factor is most important to consider when teaching correct MDI technique for ipratropium?

• Coordination of actuation with inhalation and use of a spacer if needed
• Shaking the inhaler after each actuation is unnecessary
• Holding breath is prohibited after inhalation
• Patients should exhale fully into the mouthpiece before actuation

Correct Answer: Coordination of actuation with inhalation and use of a spacer if needed

Q49. In overdose scenarios, management of ipratropium toxicity would primarily involve:

• Supportive care and, if necessary, physostigmine for severe central anticholinergic toxicity (rare for quaternary agents)
• Immediate dialysis as the first-line treatment
• Administration of naloxone to reverse effects
• Emetic therapy only

Correct Answer: Supportive care and, if necessary, physostigmine for severe central anticholinergic toxicity (rare for quaternary agents)

Q50. Which exam-focused statement summarizes ipratropium’s clinical profile?

• A short-acting inhaled antimuscarinic bronchodilator, derived from solanaceous alkaloids, used mainly in COPD and as adjunct in asthma
• A systemic corticosteroid of plant origin used for long-term asthma prophylaxis
• An oral beta-blocker used to control heart rate in COPD patients
• A powerful mucolytic enzyme derived from bacterial fermentation

Correct Answer: A short-acting inhaled antimuscarinic bronchodilator, derived from solanaceous alkaloids, used mainly in COPD and as adjunct in asthma

Download